|
- Brand:OEM
- Model:10 vials per box
- Purity:99%
- Cas:129954-34-3
- Createtime: 2026-08-28
- Updatetime: 2026-11-06
| useage | Fat cell metabolism related cell model experiments |
| deliveryInfo | |
| appearance | White crystalline powder |
| aliasen | |
| supplyCapacity | 7/ |
| Form | Lyophilized solid powder |
| harbor | |
| minorder | 1 |
Produced by solid?phase peptide synthesis and RP?HPLC purification. Each batch is strictly tested by HPLC, mass spectrum identification and endotoxin detection. Our Selank peptide features low endotoxin, stable batch?to?batch performance and excellent water?solubility, which meets international research?grade peptide standards.
Selank, also known as TP?7, is a short synthetic heptapeptide derived from tuftsin. Distinct from many metabolic?targeted peptides, it is primarily investigated for its dual regulatory effects covering immune response and central nervous?system?related signal pathways in pre?clinical laboratory settings. Its compact peptide sequence grants good aqueous solubility, simplifying solution preparation for cell and tissue?level assay systems.
Synthesis is completed via rigorous solid?phase coupling cycles, followed by preparative?scale purification to remove truncated peptide fragments and residual synthetic impurities. Mass spectrometry validates target molecular weight while HPLC monitors purity levels for every manufactured batch, minimizing experimental deviation caused by impurity interference. Common research directions include immunomodulation exploration, neuro?related cell model testing, neuropeptide interaction studies and biochemical pathway analysis.
Lyophilized Selank remains stable under sealed?20℃ dark storage. Once dissolved, peptide molecules become more vulnerable to hydrolysis. Dividing liquid samples into small single?use aliquots is strongly advised to prevent performance loss induced by repeated freeze?thaw cycles. Prepared working solutions should be kept refrigerated and utilized as quickly as possible for reliable experimental outcomes.




